The ATM facility provides IN8bio with a flexible capital source but confirms the company's urgent need for cash given the $5.1M quarterly burn rate and going-concern qualification. Monitor daily trading volumes and any placement notices for actual share sales, which will accelerate dilution. The stock is likely to trade under pressure from the ATM overhang until the company provides a clearer path to clinical milestones or partnership funding.
Price Chart
Executive Summary
IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to $2.8M of common stock, replacing its prior Cantor Fitzgerald ATM facility which was terminated. The filing confirms the company is tapping its $200M shelf registration to raise cash for clinical development and working capital, following a prior S-3/A that highlighted a $5.1M quarterly cash burn and an auditor going-concern qualification. For an $18M market cap clinical-stage biotech with no approved products, this ATM facility signals ongoing dilution risk and near-term cash needs.
Key Financial Metrics
Key Facts
- IN8bio entered into a Capital on Demand Sales Agreement with JonesTrading to sell up to $2.8M of common stock via ATM offerings
- The prior Cantor Fitzgerald ATM facility was mutually terminated on May 29, 2026 with no penalties
- The offering is under the company's existing $200M S-3 shelf registration (File No. 333-291393)
- JonesTrading will receive a 3.0% commission on gross proceeds from each sale
- The company has a $18M market cap, $21.9M cash, $5.1M quarterly cash burn, and an auditor going-concern qualification per prior filings
Financial Impact
Up to $2.8M in gross proceeds from ATM sales, representing ~15.6% of current market cap
Risk Factors
- Immediate dilution risk as the company can sell shares into the market at any time
- ATM overhang may suppress stock price as investors anticipate continuous selling
- Cash runway remains limited (~4 quarters at current burn rate) without additional financing or clinical catalysts
- No approved products or near-term revenue to offset dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249684 |
| Document: d100941d8k.htm | 0001193125-26-249684 |
| Document: d100941dex51.htm | 0001193125-26-249684 |
| Document: 0001193125-26-249684-index-headers.html | 0001193125-26-249684 |
| Document: 0001193125-26-249684-index.html | 0001193125-26-249684 |
| Document: 0001193125-26-249684.txt | 0001193125-26-249684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | Press Release | $1.54 $1.04 | ▼ −32.47% | ▼ −34.97% | $0.9804 (−36.34%) |
Jun 1, 2026 21w ago | 8-K | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9804 (+43.33%) |
Jun 1, 2026 21w ago | 424B5 | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9804 (+43.33%) |
May 18, 2026 23w ago | S-3/A | $1.45 $1.18 | ▲ +18.62% | ▲ +24.91% | $0.9804 (+32.39%) |
May 7, 2026 24w ago | 8-K | $1.58 $0.9601 | ▼ −39.23% | ▼ −44.07% | $0.9804 (−37.95%) |
Mar 26, 2026 30w ago | DEFA14A | $1.41 $1.51 | ▲ +7.09% | ▼ −8.97% | $0.9804 (−30.47%) |
Mar 12, 2026 32w ago | Press Release | $1.89 $1.44 | ▼ −23.81% | ▼ −35.42% | $0.9804 (−48.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers